NMDA
Teva recall heart drug after carcinogen found in API
June 14, 2019Medical Communications API, Contamination, NMDA, Teva, carcinogen, pharma, recall
Teva Pharmaceuticals has expanded its recall of losartan potassium tablets after detecting a possible carcinogen in an active pharmaceutical ingredient …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
